Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapeutic guidelines recommend that CYP2C19 intermediate and poor metabolizers with acute coronary syndromes undergoing percutaneous coronary intervention receive an alternative antiplatelet therapy; however, genotype-guided therapy is not a standard recommendation for neurovascular conditions.
|
31128980 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Interaction of CYP2C19 G681A polymorphism and omeprazole on clopidogrel responsiveness and impact in patients with acute coronary syndrome.
|
31658140 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the association of mandatory reporting of CYP2C19 pharmacogenomic testing, provided to investigators with no direct recommendations on how to use these results, with changes in P2Y12 inhibitor use, particularly clopidogrel, in the Randomized Trial to Compare the Safety of Rivaroxaban vs Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome (GEMINI-ACS-1) clinical trial.
|
31141104 |
2019 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
|
30760018 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome.
|
31772608 |
2019 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China.
|
29243114 |
2018 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
This relationship was first described in subjects after acute coronary syndrome due to the interference of proton pump inhibitors in the cytochrome P450 2C19 and the conversion of clopidogrel to its active metabolite.
|
29804887 |
2018 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual Antiplatelet Therapy Guided by CYP2C19 Polymorphisms after Implantation of Second-Generation Drug-Eluting Stents for Management of Acute Coronary Syndrome.
|
29279531 |
2018 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Combination of the CYP2C19 metabolizer and the GRACE risk score better predicts the long-term major adverse cardiac events in acute coronary syndrome undergoing percutaneous coronary intervention.
|
30193195 |
2018 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants.
|
29936693 |
2018 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.
|
28117433 |
2018 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
|
27924429 |
2017 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Five hundred and three patients with an acute coronary event were studied to assess the association between the CYP2C19 activity (CYP2C19*2, CYP2C19*3 and CYP2C19*17 variants) and the type of acute coronary syndrome, cardiovascular risk factors (arterial systemic hypertension, diabetes mellitus, dyslipidemia and smoking), analytical parameters and the extent and severity of coronary atherosclerosis.
|
28473221 |
2017 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic Polymorphism of CYP2C19 and Inhibitory Effects of Ticagrelor and Clopidogrel Towards Post-Percutaneous Coronary Intervention (PCI) Platelet Aggregation in Patients with Acute Coronary Syndromes.
|
27977637 |
2016 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 polymorphisms in acute coronary syndrome patients undergoing clopidogrel therapy in Zhengzhou population.
|
27323099 |
2016 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
However, the relationship of CYP2C19 genotype and outcomes in medically managed patients with acute coronary syndromes (ACS) is not known.
|
26916483 |
2016 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Effects of CYP2C19 allelic variants on inhibition of platelet aggregation and major adverse cardiovascular events in Japanese patients with acute coronary syndrome: The PRASFIT-ACS study.
|
26521100 |
2016 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.
|
26108379 |
2015 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of CYP2C19 2 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronary syndrome.
|
25542807 |
2015 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19*2 and Other Allelic Variants Affecting Platelet Response to Clopidogrel Tested by Thrombelastography in Patients with Acute Coronary Syndrome.
|
26265611 |
2015 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
|
26398625 |
2015 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalence and significance of CYP2C19*2 and CYP2C19*17 alleles in a New Zealand acute coronary syndrome population.
|
25583161 |
2015 |
Acute Coronary Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Laboratories are increasingly requested to perform CYP2C19 genetic testing when managing clopidogrel therapy, especially in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
|
26218263 |
2015 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, the present study was designed to investigate the impact of CYP2C19 loss-of-function point-of-care (POC) genotyping in patients presenting with acute coronary syndromes (ACS) and treated with dual antiplatelet therapy in the emergency setting.
|
24856643 |
2014 |
Acute Coronary Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Paths from two clinical characteristics (diabetes mellitus and acute coronary syndrome (ACS)) and two genetic variants (CYP2C19*2 and CYP2C19*17) independently predicted HTPR (path coefficients: 0.11 0.10, 0.17, and -0.10, respectively; p<0.05 for all).
|
25051347 |
2014 |